Technology, the major focus for Novartis in Hyderabad
Technology, the major focus for Novartis in Hyderabad

Novartis Pharma, the Switzerland-based pharmaceuticals manufacturer is strengthening its focus on digitalisation and data. With the company’s focus in these two areas already making an impact in the last 2-3 years, Hyderabad operations are all set to contribute to its global operations in data analytics and robotics.

The company’s chief information officer (CIO) Scott Sandschafer shared that they aim to contribute towards business both topline and bottom line, provide agility and be responsive. He stated that the technology is also helping achieve quality enhancement, regulatory compliance and operational efficiencies adding more value to the company.

Novartis Pharma is grasping the nuances of data through machine learning to garner accurate perspectives and insights of medicines on their efficacy to treat patients with the help of the huge clinical data that gets generated within the company.

With the establishment of the centre of excellence (CoE) in Hyderabad, the company has set up large teams in data analytics and robotics thus creating a strong data analytics capability.

The company intends to expand teams in Hyderabad and in other geographies globally.

Hyderabad termed as one of the foundational sites in all the areas of IT capabilities with robotics set to be a major future opportunity.

The company has five different building blocks helping to leverage the ecosystem of providers both in India and across the globe, integrated into the global operations. 

The Building blocks include service delivery, service operations, service excellence and centre of excellence.

With Novartis gaining support from technology in using data analytics to identify the right clinical sites, the drug is manufactured in a minimal timeline and analytics helps achieve better patient care outcomes.

Located in Basel, the company offers eye care along with a varied portfolio of medicines, biosimilar and cost-saving generic pharmaceuticals. 

Novartis’ products are sold in approximately 155 countries around the world.